Potential Prophylactic Treatments for COVID-19
The World Health Organization declared the SARS-CoV-2 outbreak a Public Health Emergency of International Concern at the end of January 2020 and a pandemic two months later. The virus primarily spreads between humans via respiratory droplets, and is the causative agent of Coronavirus Disease 2019 (C...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/7/1292 |
id |
doaj-d9cad27cb4ff41049c4e15a2204448d3 |
---|---|
record_format |
Article |
spelling |
doaj-d9cad27cb4ff41049c4e15a2204448d32021-07-23T14:11:27ZengMDPI AGViruses1999-49152021-07-01131292129210.3390/v13071292Potential Prophylactic Treatments for COVID-19Noam Ben-Zuk0Ido-David Dechtman1Itai Henn2Libby Weiss3Amichay Afriat4Esther Krasner5Yoav Gal6Chemical, Biological, Radiological and Nuclear Defense Division, Ministry of Defense, HaKirya, Tel-Aviv 61909, IsraelThe Israel Defense Force Medical Corps, Tel Hashomer, Military Post 02149, IsraelChemical, Biological, Radiological and Nuclear Defense Division, Ministry of Defense, HaKirya, Tel-Aviv 61909, IsraelChemical, Biological, Radiological and Nuclear Defense Division, Ministry of Defense, HaKirya, Tel-Aviv 61909, IsraelDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, IsraelChemical, Biological, Radiological and Nuclear Defense Division, Ministry of Defense, HaKirya, Tel-Aviv 61909, IsraelChemical, Biological, Radiological and Nuclear Defense Division, Ministry of Defense, HaKirya, Tel-Aviv 61909, IsraelThe World Health Organization declared the SARS-CoV-2 outbreak a Public Health Emergency of International Concern at the end of January 2020 and a pandemic two months later. The virus primarily spreads between humans via respiratory droplets, and is the causative agent of Coronavirus Disease 2019 (COVID-19), which can vary in severity, from asymptomatic or mild disease (the vast majority of the cases) to respiratory failure, multi-organ failure, and death. Recently, several vaccines were approved for emergency use against SARS-CoV-2. However, their worldwide availability is acutely limited, and therefore, SARS-CoV-2 is still expected to cause significant morbidity and mortality in the upcoming year. Hence, additional countermeasures are needed, particularly pharmaceutical drugs that are widely accessible, safe, scalable, and affordable. In this comprehensive review, we target the prophylactic arena, focusing on small-molecule candidates. In order to consolidate a potential list of such medications, which were categorized as either antivirals, repurposed drugs, or miscellaneous, a thorough screening for relevant clinical trials was conducted. A brief molecular and/or clinical background is provided for each potential drug, rationalizing its prophylactic use as an antiviral or inflammatory modulator. Drug safety profiles are discussed, and current medical indications and research status regarding their relevance to COVID-19 are shortly reviewed. In the near future, a significant body of information regarding the effectiveness of drugs being clinically studied for COVID-19 is expected to accumulate, in addition to information regarding the efficacy of prophylactic treatments.https://www.mdpi.com/1999-4915/13/7/1292SARS-CoV-2COVID-19treatmentprophylaxispre-exposurepost-exposure |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Noam Ben-Zuk Ido-David Dechtman Itai Henn Libby Weiss Amichay Afriat Esther Krasner Yoav Gal |
spellingShingle |
Noam Ben-Zuk Ido-David Dechtman Itai Henn Libby Weiss Amichay Afriat Esther Krasner Yoav Gal Potential Prophylactic Treatments for COVID-19 Viruses SARS-CoV-2 COVID-19 treatment prophylaxis pre-exposure post-exposure |
author_facet |
Noam Ben-Zuk Ido-David Dechtman Itai Henn Libby Weiss Amichay Afriat Esther Krasner Yoav Gal |
author_sort |
Noam Ben-Zuk |
title |
Potential Prophylactic Treatments for COVID-19 |
title_short |
Potential Prophylactic Treatments for COVID-19 |
title_full |
Potential Prophylactic Treatments for COVID-19 |
title_fullStr |
Potential Prophylactic Treatments for COVID-19 |
title_full_unstemmed |
Potential Prophylactic Treatments for COVID-19 |
title_sort |
potential prophylactic treatments for covid-19 |
publisher |
MDPI AG |
series |
Viruses |
issn |
1999-4915 |
publishDate |
2021-07-01 |
description |
The World Health Organization declared the SARS-CoV-2 outbreak a Public Health Emergency of International Concern at the end of January 2020 and a pandemic two months later. The virus primarily spreads between humans via respiratory droplets, and is the causative agent of Coronavirus Disease 2019 (COVID-19), which can vary in severity, from asymptomatic or mild disease (the vast majority of the cases) to respiratory failure, multi-organ failure, and death. Recently, several vaccines were approved for emergency use against SARS-CoV-2. However, their worldwide availability is acutely limited, and therefore, SARS-CoV-2 is still expected to cause significant morbidity and mortality in the upcoming year. Hence, additional countermeasures are needed, particularly pharmaceutical drugs that are widely accessible, safe, scalable, and affordable. In this comprehensive review, we target the prophylactic arena, focusing on small-molecule candidates. In order to consolidate a potential list of such medications, which were categorized as either antivirals, repurposed drugs, or miscellaneous, a thorough screening for relevant clinical trials was conducted. A brief molecular and/or clinical background is provided for each potential drug, rationalizing its prophylactic use as an antiviral or inflammatory modulator. Drug safety profiles are discussed, and current medical indications and research status regarding their relevance to COVID-19 are shortly reviewed. In the near future, a significant body of information regarding the effectiveness of drugs being clinically studied for COVID-19 is expected to accumulate, in addition to information regarding the efficacy of prophylactic treatments. |
topic |
SARS-CoV-2 COVID-19 treatment prophylaxis pre-exposure post-exposure |
url |
https://www.mdpi.com/1999-4915/13/7/1292 |
work_keys_str_mv |
AT noambenzuk potentialprophylactictreatmentsforcovid19 AT idodaviddechtman potentialprophylactictreatmentsforcovid19 AT itaihenn potentialprophylactictreatmentsforcovid19 AT libbyweiss potentialprophylactictreatmentsforcovid19 AT amichayafriat potentialprophylactictreatmentsforcovid19 AT estherkrasner potentialprophylactictreatmentsforcovid19 AT yoavgal potentialprophylactictreatmentsforcovid19 |
_version_ |
1721285454795374592 |